Abstract:Dysfunctional mitochondrial metabolism and sustained de novo lipogenesis are characteristic of non-alcoholic fatty liver disease (NAFLD), a common comorbidity of obesity and type 2 diabetes. We hypothesize that sustained de novo lipogenesis, through its biochemical relationships with mitochondria (e.g., tri-carboxylic acid (TCA) cycle) can contribute to dysfunctional oxidative flux during NAFLD. In study 1, male mice (C57BL/6JN) were fed either a low-fat (LF; 10% fat Kcal), high-fat (HF; 60% fat Kcal), or high-fructose/HF diet (HFr/HF; 34.9% fructose Kcal, 25% fat Kcal) for 24-wks. Liver mitochondria were utilized to determine oxygen consumption and were incubated in a buffer (for 5-min) to determine changes in TCA cycle intermediates, using gas chromatography-mass spectrometry (GC-MS). Plasma and liver samples were utilized for GC-MS based metabolomics and determination of gene and protein expression. In study 2, C57BL/6JN mice were provided 30% fructose in drinking water (FW) for 2-wks to induce hepatic de novo lipogenesis vs. mice given regular water (RW). Liver mitochondria were incubated in a buffer containing 1mM [ 13 C 3 ]pyruvate or 2.5mM [ 13 C 4 ]malate for 5-min. Isotopomer distribution of the TCA cycle intermediates were determined using GC-MS. Both HF and HFr/HF diets resulted in similar degrees of hepatic steatosis. However, lipogenic gene expression ( Scd1, Acyl, Fasn) and fasting plasma β-hydroxybutyrate levels were higher (p<0.001) in HFr/HF vs. HF group. Further, the feeding-to-fasting induction of genes involved in lipid oxidation ( Cpt1α, Lcad, Hmgcs2) was higher (p ≤0.01) in HFr/HF vs. HF livers. After 5-min of incubation, the HFr/HF liver mitochondria had higher (p<0.05) TCA cycle intermediates vs. the HF. The HFr/HF mitochondria also had higher expression of oxidative phosphorylation proteins and higher oxygen consumption rates (OCR), vs. the HF (p<0.05). In study 2, fructose in drinking water induced hepatic de novo lipogenesis. Induction of lipogenesis was also accompanied by higher mitochondrial OCR, higher reactive oxygen species, and higher TCA cycle metabolism (p<0.05). Gene expression of components of the mitochondrial nutrient shuttles ( SLC25A13, MPC1, MPC2, ME1) was upregulated in lipogenic livers (p<0.05). Incorporation of 13 C from [ 13 C 4 ]malate into pyruvate and α-ketoglutarate, indices of malic enzyme and TCA cycle activity, were higher (p<0.05) in lipogenic livers. Similarly, incorporation of 13 C from [ 13 C 3 ]pyruvate into aspartate and citrate, indices of pyruvate carboxylase and pyruvate dehydrogenase activity, were also higher (p<0.05) in lipogenic livers. These results demonstrate that the induction of several facets of mitochondrial oxidative metabolism and de novo lipogenesis accompany a carbohydrate-rich dietary milieu and NAFLD. Sustained induction of both de novo lipogenesis and mitochondrial oxidative function could contribute to the progression of metabolic dysfunction during NAFLD. National Institutes of Health R01 DK112865 This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Metabolic pathways promoting intrahepatic fatty acid accumulation in methionine and choline deficiency: implications for the pathogenesis of steatohepatitis.

A CDAHFD-induced mouse model mimicking human NASH in the metabolism of hepatic phosphatidylcholines and acyl carnitines

A methionine-choline-deficient diet induces nonalcoholic steatohepatitis and alters the lipidome, metabolome, and gut microbiome profile in the C57BL/6J mouse

Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis

Peroxisome Proliferator-Activated Receptor Γ Coactivator 1α Maintains NAD+ Bioavailability Protecting Against Steatohepatitis

Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer

Multi-technique comparison of atherogenic and MCD NASH models highlights changes in sphingolipid metabolism

Metabolically induced liver inflammation leads to NASH and differs from LPS- or IL-1β-induced chronic inflammation

Fatty Acids Promote Fatty Liver Disease Via the Dysregulation of 3-Mercaptopyruvate Sulfurtransferase/hydrogen Sulfide Pathway.

Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis

Characterization of a murine nonalcoholic steatohepatitis model induced by high fat high calorie diet plus fructose and glucose in drinking water

Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease

Hepatocyte steatosis activates macrophage inflammatory response accelerating atherosclerosis development

Novel Choline-Deficient and 0.1%-Methionine-Added High-Fat diet Induces Burned-Out Metabolic-Dysfunction-Associated Steatohepatitis with Inflammation by Rapid Immune Cell Infiltration on Male Mice

Mitochondrial Cholesterol Metabolites in a Bile Acid Synthetic Pathway Drive Nonalcoholic Fatty Liver Disease: A Revised "Two-Hit" Hypothesis

Nonalcoholic steatohepatitis-associated hepatocarcinogenesis in mice fed a modified choline-deficient, methionine-lowered, L-amino acid-defined diet and the role of signal changes

Impact of sustained de novo lipogenesis on mitochondrial dysfunction and hepatocellular redox during fatty liver disease

Deficient Chaperone‐Mediated Autophagy in Macrophage Aggravates Inflammation of Nonalcoholic Steatohepatitis by Targeting Nup85

The Different Mechanisms of Lipid Accumulation in Hepatocytes Induced by Oleic Acid/Palmitic Acid and High-Fat Diet

Insulin dysregulation drives mitochondrial cholesterol metabolite accumulation: initiating hepatic toxicity in nonalcoholic fatty liver disease

Progression and Regression of Hepatic Lesions in a Mouse Model of NASH Induced by Dietary Intervention and Its Implications in Pharmacotherapy